Form 4: Director Renee Ryan Receives NeuroPace Equity Grant

Director Renee Ryan acquired 2,890 shares of common stock and 5,368 stock options as part of a standard equity compensation grant.

Summary

• Director Renee Ryan was granted 2,890 shares of common stock on June 5, 2026.
• Director Renee Ryan was granted 5,368 stock options with an exercise price of $15.74.
• Both the common stock and the stock options vest in twelve equal consecutive monthly installments, contingent upon continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Equity grants align the interests of the director with those of the shareholders.
• Vesting schedule encourages long-term retention of board leadership.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future value of equity is dependent on the company's ability to maintain or grow its share price above the $15.74 exercise price.

Future Outlook

The equity grants are subject to a 12-month vesting schedule, indicating a commitment to the company's performance over the coming year.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the medical device sector to ensure alignment with long-term shareholder value.

Comparison to Industry Standards

• The use of monthly vesting over one year is a standard retention mechanism for board members in the healthcare technology industry.
• The grant size is consistent with typical non-employee director compensation packages for small-cap medical device companies.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Director to complete 12 months of service to fully vest in the granted equity.

Key Dates

Keywords

NeuroPace, NPCE, Form 4, Insider Trading, Equity Compensation, Director Compensation